Antisense therapy for hormone-regulated tumors

Details Antisense therapy for hormone-regulated tumors Antisense therapy for hormone-regulated tumors

2007-09-04

2009-02-17

Angell, J. E. (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A

Reexamination Certificate

active

07491816

ABSTRACT:
A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No. 1), which is derived from the murine gene sequence, and CGCCGTGAGCAACACCAT (Seq. ID. No. 3) and AGGTCATGCACCAGCCGC (Seq. ID No. 4), which are derived from the human gene sequence.

REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 2003/0087857 (2003-05-01), Freier
patent: 2004/0009491 (2004-01-01), Birse et al.
patent: 2090702 (1992-03-01), None
patent: 2090705 (1992-03-01), None
Opalinska et al., Nucleic-acid therapeutics: Basic principles and recent applications, Jul. 2002, Nature Reviews Drug Discovery, vol. 1, pp. 503-514.
Agrawal, Sudhir, Antisense oligonucleotides: toward clinical trials, TIBTECH, Oct. 1996, vol. 14, pp. 376-387.
Andress, Dennis L. et al., Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action, Journal of Biological Chemistry, Nov. 5, 1992, vol. 267, No. 31, pp. 22467-22472.
Branch, Andrea D., A good antisense molecule is hard to find, TIBS 23, Feb. 1998, pp. 45-50.
Figueroa, Jose A. et al., Differential expression of insulin-like growth factor binding proteins in high verses low Gleason score prostate cancer, Journal of Urology, Apr. 1998, vol. 159, No. 4, pp. 1379-1383.
Gewirtz, Alan M. et al., Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci. USA, Apr. 1996, vol. 93, pp. 3161-3163.
Gregory, Christopher W. et al., Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft, Endocrinology, 1999, vol. 140, No. 5, pp. 2372-2381.
Huynh, Hung et al., A role for insulin-like growth factor binding protein-5 in the antiproliferative action of the antiestrogen ICI 182780, Cell Growth & Differentiation, Nov. 1996, vol. 7, No. 11, pp. 1501-1506.
Miyake, Hideaki et al., Castration-induced up-regulation of insulin-like growth factor bindng protein-5 potentiates insulin-like growth factor-l activity and accelearates progression to androgen independence in prostate cancer models, Cancer Research, Jun. 1, 2000, vol. 60, No. 11, pp. 3058-3064.
Miyake, Hideaki et al., Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway, Endocrinology, 2000, vol. 141, No. 6, pp. 2257-2265.
Nickerson, Tara et al., Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5, Endocrinology, Feb. 1998, vol. 139, No. 2, pp. 807-810.
Nickerson, Tara et al., Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins, Cancer Research, Jul. 15, 1999, vol. 59, No. 14, pp. 3392-3395.
Reuters news release, Lily, Isis drug fails in trial, Mar. 17, 2003.
Tamm, Ingo et al., Antisense therapy in oncology: new hope for an old idea?, The Lancet, Aug. 11, 2001, vol. 358, pp. 489-497.

Affiliated with

Also associated with

Rating

Antisense therapy for hormone-regulated tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense therapy for hormone-regulated tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense therapy for hormone-regulated tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4106137